Qianqian Wang

Qianqian Wang


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2026 in Cellular Oncology
Verified
Journal Article
Open access
XWXiaodong Wang
Xiaodong Wang
DXDi Xiong
Di Xiong
SCSongli Cui
Songli Cui
BDBingchen Duan
Bingchen Duan
GDGouping Ding
Gouping Ding
QWQianqian Wang
Qianqian Wang
Lactate is no longer viewed as a passive end-product of the Warburg effect; instead, it plays an active role in shaping tumor biology and immune responses. In solid tumors, enhanced glycolysis and lactate export, along with proton handling, generate steep lactate and acidosis gradients that exert selective pressure on immune cells. Beyond competition for resources, lactate signals through specific receptors and drives epigenetic changes via lactylation, altering the transcriptional profiles of tumor, stromal, and immune cells. These processes lead to the suppression of cytotoxic T cells and natural killer cells, impair antigen presentation, and promote regulatory T cells and myeloid suppressor cells, which collectively contribute to the development of immune-resistant “cold” microenvironments. Targeting the lactate signaling pathway, whether by inhibiting lactate production, transport, pH buffering, or receptor signaling, provides a promising strategy to counteract metabolic immune suppression. This review integrates recent findings on lactate-driven immune remodeling, identifies potential therapeutic targets, and discusses how these strategies can be combined with immunotherapy and cellular treatments to improve outcomes. We also highlight the need for biomarkers to assess lactate-specific effects and distinguish them from those caused by acidosis.

26 October 2026 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
JWJunjie Wang
Junjie Wang
XWXiaodong Wang
Xiaodong Wang
QWQianqian Wang
Qianqian Wang
DXDi Xiong
Di Xiong
SCSongli Cui
Songli Cui
YFYeqian Feng
Yeqian Feng
Immune checkpoint inhibitors (ICIs) have reshaped cancer therapy, yet durable benefit remains limited to a subset of patients. Current biomarkers, includin

20 September 2026 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
JLJiayi Liu
Jiayi Liu
AHAlifujiang Hairulajiang
Alifujiang Hairulajiang
JWJunjie Wang
Junjie Wang
QWQianqian Wang
Qianqian Wang
YFYeqian Feng
Yeqian Feng
PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resi

31 July 2026 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
XWXiaodong Wang
Xiaodong Wang
QWQianqian Wang
Qianqian Wang
WGWei Gao
Wei Gao
SHSongjiang He
Songjiang He
DXDi Xiong
Di Xiong
BZBingwen Zou
Bingwen Zou
Immune checkpoint blockade has redefined cancer therapy, yet durable responses remain constrained by resistance states that arise from coordinated tumor-ce